EdgarLookup

RPM INTERNATIONAL INC/DE/ — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that RPM INTERNATIONAL INC/DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
44.2%
Profit Margin
Net income ÷ revenue
8.9%
Return on Assets
Net income ÷ assets
+41.3%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2018 May 31, 2018 $1.56B Jul 23, 2018
FY2018 Feb 28, 2018 $1.10B Jul 23, 2018
FY2018 Nov 30, 2017 $1.32B Jul 23, 2018
FY2018 Aug 31, 2017 $1.35B Jul 23, 2018
FY2018 May 31, 2017 $1.49B Jul 23, 2018
FY2018 Feb 28, 2017 $1.02B Jul 23, 2018
FY2018 Nov 30, 2016 $1.19B Jul 23, 2018
FY2018 Aug 31, 2016 $1.25B Jul 23, 2018
FY2018 May 31, 2016 $4.81B Jul 23, 2018

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $7.37B Jul 24, 2025
FY2025 May 31, 2024 $7.34B Jul 24, 2025
FY2025 May 31, 2023 $7.26B Jul 24, 2025
FY2024 May 31, 2022 $6.71B Jul 25, 2024
FY2023 May 31, 2021 $6.11B Jul 26, 2023
FY2020 May 31, 2020 $1.46B Jul 27, 2020
FY2020 Feb 29, 2020 $1.17B Jul 27, 2020
FY2020 Nov 30, 2019 $1.40B Jul 27, 2020
FY2020 Aug 31, 2019 $1.47B Jul 27, 2020
FY2020 May 31, 2019 $1.60B Jul 27, 2020

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 May 31, 2017 $1.49B Jul 24, 2017
FY2017 Feb 28, 2017 $1.02B Jul 24, 2017
FY2017 Nov 30, 2016 $1.19B Jul 24, 2017
FY2017 Aug 31, 2016 $1.25B Jul 24, 2017
FY2017 May 31, 2016 $1.43B Jul 24, 2017
FY2017 Feb 29, 2016 $988.56M Jul 24, 2017
FY2017 Nov 30, 2015 $1.16B Jul 24, 2017
FY2017 Aug 31, 2015 $1.24B Jul 24, 2017
FY2016 May 31, 2015 $1.37B Jul 28, 2016
FY2016 Feb 28, 2015 $946.37M Jul 28, 2016

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $3.05B Jul 24, 2025
FY2025 May 31, 2024 $3.01B Jul 24, 2025
FY2025 May 31, 2023 $2.75B Jul 24, 2025
FY2024 May 31, 2022 $2.43B Jul 25, 2024
FY2023 May 31, 2021 $2.41B Jul 26, 2023
FY2020 May 31, 2020 $553.96M Jul 27, 2020
FY2020 Feb 29, 2020 $434.75M Jul 27, 2020
FY2020 Nov 30, 2019 $529.40M Jul 27, 2020
FY2020 Aug 31, 2019 $574.75M Jul 27, 2020
FY2020 May 31, 2019 $635.81M Jul 27, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $688.69M Jul 24, 2025
FY2025 May 31, 2024 $588.40M Jul 24, 2025
FY2025 May 31, 2023 $478.69M Jul 24, 2025
FY2024 May 31, 2022 $491.48M Jul 25, 2024
FY2023 May 31, 2021 $502.64M Jul 26, 2023
FY2020 May 31, 2020 $109.31M Jul 27, 2020
FY2020 Feb 29, 2020 $11.85M Jul 27, 2020
FY2020 Nov 30, 2019 $77.03M Jul 27, 2020
FY2020 Aug 31, 2019 $106.19M Jul 27, 2020
FY2020 May 31, 2019 $133.38M Jul 27, 2020

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $94.70M Jul 24, 2025
FY2025 May 31, 2024 $92.20M Jul 24, 2025
FY2025 May 31, 2023 $86.60M Jul 24, 2025
FY2024 May 31, 2022 $80.50M Jul 25, 2024
FY2023 May 31, 2021 $77.60M Jul 26, 2023
FY2022 May 31, 2020 $76.50M Jul 25, 2022
FY2021 May 31, 2019 $71.60M Jul 26, 2021
FY2020 May 31, 2018 $69.70M Jul 27, 2020
FY2019 May 31, 2017 $64.90M Jul 24, 2019
FY2018 May 31, 2016 $61.50M Jul 23, 2018

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $2.15B Jul 24, 2025
FY2025 May 31, 2024 $2.11B Jul 24, 2025
FY2025 May 31, 2023 $1.96B Jul 24, 2025
FY2024 May 31, 2022 $1.79B Jul 25, 2024
FY2023 May 31, 2021 $1.66B Jul 26, 2023
FY2022 May 31, 2020 $1.55B Jul 25, 2022
FY2021 May 31, 2019 $1.60B Jul 26, 2021
FY2020 May 31, 2018 $1.50B Jul 27, 2020
FY2019 May 31, 2017 $1.64B Jul 24, 2019
FY2018 May 31, 2016 $1.52B Jul 23, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $768.19M Jul 24, 2025
FY2025 May 31, 2024 $1.12B Jul 24, 2025
FY2025 May 31, 2023 $577.11M Jul 24, 2025
FY2024 May 31, 2022 $178.73M Jul 25, 2024
FY2023 May 31, 2021 $766.16M Jul 26, 2023
FY2022 May 31, 2020 $549.92M Jul 25, 2022
FY2021 May 31, 2019 $292.94M Jul 26, 2021
FY2020 May 31, 2018 $390.38M Jul 27, 2020
FY2019 May 31, 2017 $386.13M Jul 24, 2019
FY2018 May 31, 2016 $474.71M Jul 23, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $7.78B Jul 24, 2025
FY2025 May 31, 2024 $6.59B Jul 24, 2025
FY2024 May 31, 2023 $6.78B Jul 25, 2024
FY2024 May 31, 2022 $6.71B Jul 25, 2024
FY2023 May 31, 2021 $6.25B Jul 26, 2023
FY2022 May 31, 2020 $5.63B Jul 25, 2022
FY2021 May 31, 2019 $5.44B Jul 26, 2021
FY2020 May 31, 2018 $5.27B Jul 27, 2020
FY2019 May 31, 2017 $5.09B Jul 24, 2019
FY2018 May 31, 2016 $4.76B Jul 23, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $2.89B Jul 24, 2025
FY2025 May 31, 2024 $2.51B Jul 24, 2025
FY2024 May 31, 2023 $2.14B Jul 25, 2024
FY2023 May 31, 2022 $1.98B Jul 26, 2023
FY2022 May 31, 2021 $1.74B Jul 25, 2022
FY2021 May 31, 2020 $1.26B Jul 26, 2021
FY2020 May 31, 2019 $1.41B Jul 27, 2020
FY2019 May 31, 2018 $1.63B Jul 24, 2019
FY2018 May 31, 2017 $1.44B Jul 23, 2018
FY2017 May 31, 2016 $1.37B Jul 24, 2017

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $1.62B Jul 24, 2025
FY2025 May 31, 2024 $1.31B Jul 24, 2025
FY2025 May 31, 2023 $1.29B Jul 24, 2025
FY2024 May 31, 2022 $1.34B Jul 25, 2024
FY2023 May 31, 2021 $1.35B Jul 26, 2023
FY2022 May 31, 2020 $1.25B Jul 25, 2022
FY2021 May 31, 2019 $1.25B Jul 26, 2021
FY2020 May 31, 2018 $1.19B Jul 27, 2020
FY2019 May 31, 2017 $1.14B Jul 24, 2019
FY2018 May 31, 2016 $1.22B Jul 23, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $3.19B Jul 24, 2025
FY2025 May 31, 2024 $2.76B Jul 24, 2025
FY2024 May 31, 2023 $2.40B Jul 25, 2024
FY2023 May 31, 2022 $2.14B Jul 26, 2023
FY2022 May 31, 2021 $1.85B Jul 25, 2022
FY2021 May 31, 2020 $1.54B Jul 26, 2021
FY2020 May 31, 2019 $1.43B Jul 27, 2020
FY2019 May 31, 2018 $1.34B Jul 24, 2019
FY2018 May 31, 2017 $1.17B Jul 23, 2018
FY2017 May 31, 2016 $1.15B Jul 24, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 $302.14M Jul 24, 2025
FY2025 May 31, 2024 $237.38M Jul 24, 2025
FY2024 May 31, 2023 $215.79M Jul 25, 2024
FY2023 May 31, 2022 $201.67M Jul 26, 2023
FY2022 May 31, 2021 $246.70M Jul 25, 2022
FY2021 May 31, 2020 $233.42M Jul 26, 2021
FY2020 May 31, 2019 $223.17M Jul 27, 2020
FY2019 May 31, 2018 $244.42M Jul 24, 2019
FY2019 May 31, 2017 $350.50M Jul 24, 2019
FY2019 May 31, 2016 $265.15M Jul 24, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2013 May 31, 2013 $1.37B Jul 24, 2013
FY2012 May 31, 2012 $1.12B Jul 26, 2012
FY2012 May 31, 2011 $1.11B Jul 26, 2012

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 5 Jul 24, 2025
FY2025 May 31, 2024 4 Jul 24, 2025
FY2025 May 31, 2023 3 Jul 24, 2025
FY2024 May 31, 2022 3 Jul 25, 2024
FY2023 May 31, 2021 3 Jul 26, 2023
FY2020 May 31, 2020 0 Jul 27, 2020
FY2020 Feb 29, 2020 0 Jul 27, 2020
FY2020 Nov 30, 2019 0 Jul 27, 2020
FY2020 Aug 31, 2019 0 Jul 27, 2020
FY2020 May 31, 2019 1 Jul 27, 2020

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 5 Jul 24, 2025
FY2025 May 31, 2024 4 Jul 24, 2025
FY2025 May 31, 2023 3 Jul 24, 2025
FY2024 May 31, 2022 3 Jul 25, 2024
FY2023 May 31, 2021 3 Jul 26, 2023
FY2020 May 31, 2020 0 Jul 27, 2020
FY2020 Feb 29, 2020 0 Jul 27, 2020
FY2020 Nov 30, 2019 0 Jul 27, 2020
FY2020 Aug 31, 2019 0 Jul 27, 2020
FY2020 May 31, 2019 1 Jul 27, 2020

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 May 31, 2025 128.27M Jul 24, 2025
FY2025 May 31, 2024 128.63M Jul 24, 2025
FY2024 May 31, 2023 128.77M Jul 25, 2024
FY2023 May 31, 2022 129.20M Jul 26, 2023
FY2022 May 31, 2021 129.57M Jul 25, 2022
FY2021 May 31, 2020 129.51M Jul 26, 2021
FY2020 May 31, 2019 131.00M Jul 27, 2020
FY2019 May 31, 2018 133.65M Jul 24, 2019
FY2018 May 31, 2017 133.56M Jul 23, 2018
FY2017 May 31, 2016 132.94M Jul 24, 2017